KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Liabilities and Shareholders Equity: 2018-2024

Historic Liabilities and Shareholders Equity for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $531.2 million.

  • Castle Biosciences' Liabilities and Shareholders Equity rose 9.37% to $562.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 11.85%. This contributed to the annual value of $531.2 million for FY2024, which is 17.18% up from last year.
  • Castle Biosciences' Liabilities and Shareholders Equity amounted to $531.2 million in FY2024, which was up 17.18% from $453.3 million recorded in FY2023.
  • Castle Biosciences' Liabilities and Shareholders Equity's 5-year high stood at $531.2 million during FY2024, with a 5-year trough of $439.3 million in FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $453.3 million (2023), whereas its average is $477.3 million.
  • In the last 5 years, Castle Biosciences' Liabilities and Shareholders Equity skyrocketed by 266.88% in 2020 and then declined by 3.30% in 2022.
  • Over the past 5 years, Castle Biosciences' Liabilities and Shareholders Equity (Yearly) stood at $439.3 million in 2020, then climbed by 5.29% to $462.6 million in 2021, then declined by 3.30% to $447.3 million in 2022, then climbed by 1.34% to $453.3 million in 2023, then rose by 17.18% to $531.2 million in 2024.